Search results for "Myeloid"

showing 10 items of 538 documents

A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells.

2006

Abstract The FLT3 receptor tyrosine kinase is expressed in more than 90% of acute myelogeneous leukemias (AMLs), up to 30% of which carry an internal tandem duplication (ITD) within the FLT3 gene. Although varying duplication sites exist, most FLT3-ITDs affect a single protein domain. We analyzed the FLT3-ITD of an AML patient for encoding HLA class I–restricted immunogenic peptides. One of the tested peptides (YVDFREYEYY) induced in vitro autologous T-cell responses restricted by HLA-A*0101 that were also detectable ex vivo. These peptide-reactive T cells recognized targets transfected with the patient's FLT3-ITD, but not wild-type FLT3, and recognized the patient's AML cells. Our results …

FLT3 Internal Tandem DuplicationMyeloidmedicine.medical_treatmentImmunologyAntigen presentationMolecular Sequence DataHuman leukocyte antigenBiologyCD8-Positive T-LymphocytesIn Vitro TechniquesTransfectionBiochemistryCell LineEpitopesfluids and secretionshemic and lymphatic diseasesCell Line TumorGene DuplicationGene duplicationmedicineCytotoxic T cellHumansAmino Acid SequenceRNA MessengerHLA-A1 AntigenAntigen PresentationHLA-A Antigenshemic and immune systemsCell BiologyHematologyImmunotherapymedicine.diseaseMolecular biologyLeukemiaLeukemia Myeloid Acutemedicine.anatomical_structurefms-Like Tyrosine Kinase 3embryonic structurespsychological phenomena and processesBlood
researchProduct

Next-Generation Sequencing (NGS)-Based Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication (…

2020

Background: FLT3-ITD occurs in ~25% of adult AML patients (pts) and is associated with poor prognosis. MRD monitoring is of high prognostic relevance, but restricted to certain AML subtypes. FLT3-ITD represents an attractive target for MRD monitoring in particular in pts treated with a tyrosine kinase inhibitor. FLT3-ITD MRD monitoring is hampered by the broad heterogeneity of ITD length and insertion site (IS). NGS may overcome these limitations offering the opportunity for MRD monitoring in FLT3-ITD+ AML. Aims: To validate our recently established NGS-based FLT3-ITD MRD assay in a defined cohort of FLT3-ITD+ AML pts treated within the AMLSG16-10 trial (NCT01477606) combining intensive che…

FLT3 Internal Tandem Duplicationbusiness.industryImmunologyMyeloid leukemiaCell BiologyHematologyDiseaseBiochemistryDNA sequencingchemistry.chemical_compoundchemistryCancer researchMedicineMidostaurinbusinessFlt3 itdBlood
researchProduct

WT1 isoform expression pattern in acute myeloid leukemia.

2013

WT1 plays a dual role in leukemia development, probably due to an imbalance in the expression of the 4 main WT1 isoforms. We quantify their expression and evaluate them in a series of AML patients. Our data showed a predominant expression of isoform D in AML, although in a lower quantity than in normal CD34+ cells. We found a positive correlation between the total WT1 expression and A, B and C isoforms. The overexpression of WT1 in AML might be due to a relative increase in A, B and C isoforms, together with a relative decrease in isoform D expression.

Gene isoformAdultMalecongenital hereditary and neonatal diseases and abnormalitiesCancer ResearchAdolescentCD34HL-60 CellsBiologyurologic and male genital diseasesPositive correlationCohort StudiesYoung AdultDual roleExpression patternhemic and lymphatic diseasesmedicineTumor Cells CulturedHumansProtein IsoformsWT1 ProteinsAgedAged 80 and overurogenital systemGene Expression Regulation LeukemicGene Expression ProfilingMyeloid leukemiaHematologyMiddle Agedmedicine.diseaseMolecular biologyfemale genital diseases and pregnancy complicationsLeukemiaLeukemia Myeloid AcuteOncologyCase-Control StudiesFemaleK562 CellsLeukemia research
researchProduct

Targeting Aberrant Ncam (neural cell adhesion molecule; CD56) Expression in Acute Myeloid Leukemia

2015

Abstract Background Acute myeloid leukemia (AML) is a heterogeneous disease of the hematopoietic progenitor cell driven by the subsequent acquisition of genetic alterations. Approximately 20% of AML patients show strong expression of CD56 (neural cell adhesion molecule; NCAM). Expression of NCAM is associated with poor overall survival; however, the functional role of aberrant NCAM expression has not been investigated to date. The goal of this study is to examine the biological role of NCAM in AML and to explore whether NCAM represents a potential therapeutic target. Results In order to evaluate the clinical significance of elevated NCAM expression in AML, we screened a panel of human cell …

Gene knockdownChemistryCell growthImmunologyCellMyeloid leukemiaCell BiologyHematologymedicine.diseaseBiochemistryLeukemiamedicine.anatomical_structurenervous systemCell cultureCancer researchmedicineNeural cell adhesion moleculeK562 cellsBlood
researchProduct

Expression Of FLT3-ITD Dysregulates The DBC1-Sirt1-p53 Signaling and Promotes Therapy Resistance

2013

Abstract Background SIRT1 is a NAD+ dependent histone deacetylase, which has been shown to act as an important regulator of apoptosis, DNA-repair and is involved in the maintenance of genetic integrity under conditions of cellular stress. Beside deacetylation of histones H4K16, SIRT1 has numeral other substrates including KU70, FOXO1 or p53. SIRT1 deacetylates p53 at lysine 382 thereby reducing its transcriptional activity followed by loss of p53 dependent apoptosis in response to cell damage. The activity of SIRT1 is negatively regulated by DBC1 (Deleted in Breast Cancer 1) and involves protein–protein interaction (Kim et al., Nature 2008). Recent reports have demonstrated increased expres…

Gene knockdownImmunologyMyeloid leukemiaCell BiologyHematologyBiologyBiochemistryMolecular biologychemistry.chemical_compoundchemistryhemic and lymphatic diseasesCancer cellCancer researchMidostaurinStem cellSignal transductionKinase activityTyrosine kinaseBlood
researchProduct

Lentivirus-induced dendritic cells for immunization against high-risk WT1(+) acute myeloid leukemia.

2013

Wilms' tumor 1 antigen (WT1) is overexpressed in acute myeloid leukemia (AML), a high-risk neoplasm warranting development of novel immunotherapeutic approaches. Unfortunately, clinical immunotherapeutic use of WT1 peptides against AML has been inconclusive. With the rationale of stimulating multiantigenic responses against WT1, we genetically programmed long-lasting dendritic cells capable of producing and processing endogenous WT1 epitopes. A tricistronic lentiviral vector co-expressing a truncated form of WT1 (lacking the DNA-binding domain), granulocyte-macrophage colony-stimulating factor (GM-CSF), and interleukin-4 (IL-4) was used to transduce human monocytes ex vivo. Overnight transd…

Genes Wilms TumorCell SurvivalGenetic VectorsAntineoplastic AgentsBiologyCD8-Positive T-LymphocytesLymphocyte ActivationPeripheral blood mononuclear cellEpitopeMonocytesViral vectorMiceAntigenRisk FactorsGeneticsmedicineNeoplasmAnimalsHumansMolecular BiologyResearch ArticlesOligonucleotide Array Sequence AnalysisCD86LentivirusGene Transfer TechniquesMyeloid leukemiaGranulocyte-Macrophage Colony-Stimulating FactorCell DifferentiationDendritic CellsGenetic Therapymedicine.diseaseAdoptive TransferLeukemia Myeloid AcuteGene Expression RegulationCancer researchLeukocytes MononuclearMolecular MedicineInterleukin-4Ex vivoHuman gene therapy
researchProduct

Cdc42 in osterix-expressing cells alters osteoblast behavior and myeloid lineage commitment

2021

Osteoblasts are not only responsible for bone formation. They also support hematopoiesis. This requires responding to cues originating from several signaling pathways, a task performed by Rho GTPases. We therefore examined several transgenic mouse models and used inhibitors of Cdc42 in vitro. Deletion of Cdc42 in vivo using the Osterix promoter suppressed osteoblast function, while its deletion in differentiating osteoblasts using the Collagen-a1(I) promoter decreased osteoblast numbers. In both cases, bone mineral density diminished confirming the importance of Cdc42. Evaluation of hematopoiesis revealed that deletion of Cdc42 using the Osterix, but not the Collagen-a1(I) promoter increase…

Genetically modified mousemusculoskeletal diseasesOsteoblastsHistologyMyeloidStromal cellPhysiologyChemistryEndocrinology Diabetes and MetabolismCell DifferentiationOsteoblastmacromolecular substancesBone and BonesCell biologyMiceHaematopoiesismedicine.anatomical_structureOsteogenesismedicineAnimalsCell LineageMyelopoiesisBone marrowSignal transduction
researchProduct

Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myleoid Leukemia: Comparison with FISH and PCR Techniques

2015

Chronic Myeloid Leukemia (CML) is characterized by a balanced translocation juxtaposing the Abelson (ABL) and breakpoint cluster region (BCR) genes. The resulting BCR-ABL1 oncogene leads to increased proliferation and survival of leukemic cells. Successful treatment of CML has been accompanied by steady improvements in our capacity to accurately and sensitively monitor therapy response. Currently, measurement of BCR-ABL1 mRNA transcript levels by real-time quantitative PCR (RQ-PCR) defines critical response endpoints. An antibody-based technique for BCR-ABL1 protein recognition could be an attractive alternative to RQ-PCR. To date, there have been no studies evaluating whether flow-cytometr…

Genetics and Molecular Biology (all)medicine.medical_specialtyScienceFusion Proteins bcr-ablBiologyBiochemistryPolymerase Chain ReactionInternal medicinehemic and lymphatic diseasesmedicineHumansAgricultural and Biological Sciences (all); Biochemistry Genetics and Molecular Biology (all); Medicine (all)In Situ Hybridization FluorescenceImmunoassayMultidisciplinaryABLHematologymedicine.diagnostic_testMedicine (all)QRbreakpoint cluster regionMyeloid leukemiaLeukemia Myelomonocytic Chronicmedicine.diseaseFlow CytometryMolecular biologyFusion proteinLeukemiaReal-time polymerase chain reactionAgricultural and Biological Sciences (all)ImmunoassayMedicineResearch ArticlePLoS ONE
researchProduct

Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreas

2022

Undifferentiated sarcomatoid carcinoma (USC) of the pancreas is a rare but especially aggressive variant of pancreatic ductal adenocarcinoma (PDAC), composed of at least 80% of sarcomatoid cells. This study aimed to elucidate its clinicopathological and molecular features. The study cohort included 10 patients with pancreatic USC. Clinicopathological parameters were determined for each patient. The molecular profile was investigated using next-generation sequencing (NGS). Histologically, all tumors were hypercellular neoplasms with spindle-shaped or sarcomatoid cells. All patients showed vascular and perineural invasion. Most patients had a poor prognosis. NGS showed important similarities …

GenomicsPancreatic cancerAdenocarcinomaKRAS; Pancreatic cancer; Pancreatic ductal adenocarcinoma; Sarcomatoid; UndifferentiatedSarcomatoidPathology and Forensic MedicineKRAS Pancreatic cancer Pancreatic ductal adenocarcinoma Sarcomatoid UndifferentiatedPancreatic NeoplasmsProto-Oncogene Proteins p21(ras)Pancreatic ductal adenocarcinomaMutationUndifferentiatedKRASHumansMyeloid Cell Leukemia Sequence 1 ProteinPancreasCarcinoma Pancreatic Ductal
researchProduct

Parental occupational pesticide exposure and the risk of childhood leukemia in the offspring: Findings from the childhood leukemia international cons…

2014

Maternal occupational pesticide exposure during pregnancy and/or paternal occupational pesticide exposure around conception have been suggested to increase risk of leukemia in the offspring. With a view to providing insight in this area we pooled individual level data from 13 case-control studies participating in the Childhood Leukemia International Consortium (CLIC). Occupational data were harmonized to a compatible format. Pooled individual analyses were undertaken using unconditional logistic regression. Using exposure data from mothers of 8,236 cases, and 14,850 controls, and from fathers of 8,169 cases and 14,201 controls the odds ratio (OR) for maternal exposure during pregnancy and t…

GerontologyCancer ResearchPregnancymedicine.medical_specialtyChildhood leukemiabusiness.industryObstetricsOffspringMyeloid leukemiaOdds ratiomedicine.diseaseConfidence intervalLeukemiaPaternal ExposureOncologyMedicinebusinessInternational Journal of Cancer
researchProduct